ReviewUpdates in surgery2026
Exploring the frontier: promising survival in selected patients after CRS and HIPEC for peritoneal metastases from hepatocellular carcinoma-a systematic review.
Review in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma with peritoneal metastases (HCC-PM) is a rare and aggressive disease with limited therapeutic options and poor prognosis under systemic treatments. Recent evidence suggests that cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may provide a survival benefit in selected patients. This systematic review aims to assess the effectiveness and safety of CRS + HIPEC in the management of HCC-PM. This study was conducted according to PRISMA guidelines and registered in PROSPERO(CRD42024627130). We systematically searched MEDLINE, Web of Science, and Scopus up to December 17, 2024. Eligible studies included adults with HCC-PM treated with CRS + HIPEC, reporting outcomes on postoperative complications, overall survival (OS), and disease-free survival (DFS). Risk of bias was assessed using the Newcastle-Ottawa Scale. Six retrospective studies, encompassing 57 patients, were included. Peritoneal Cancer Index (PCI) ranged from 2 to 35. The most used HIPEC agents were mitomycin-C and cisplatin, although none are standard systemic therapies for HCC. Major postoperative complications ranged from 16.6 to 47.6%. No intraoperative deaths were reported, but one perioperative death occurred in a patient with high PCI and incomplete cytoreduction. Median OS ranged from 15.7 to 49.9 months, while DFS ranged from 5.0 to 26.3 months. Lower PCI, complete cytoreduction (CCR-0/1), preserved liver function and good performance status were associated with improved outcomes. CRS + HIPEC appears to be a feasible therapeutic option for selected HCC-PM patients, potentially offering superior survival outcomes compared to systemic therapy alone. However, high morbidity rates, recurrence risk, and heterogeneous protocols highlight the need for standardized approaches and prospective clinical trials to define its role in this population.
Indexed as
Identifiers
41629485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.